BiotechTube

Milciclib Dose: 150 mg/day Mode of administration: oral

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NSCLC

Conditions

NSCLC

Trial Timeline

Mar 15, 2023 → Jun 1, 2025

NCT ID
NCT05651269

About Milciclib Dose: 150 mg/day Mode of administration: oral

Milciclib Dose: 150 mg/day Mode of administration: oral is a phase 2 stage product being developed by Tiziana Life Sciences for NSCLC. The current trial status is unknown. This product is registered under clinical trial identifier NCT05651269. Target conditions include NSCLC.

What happened to similar drugs?

7 of 20 similar drugs in NSCLC were approved

Approved (7) Terminated (3) Active (11)
✅DurvalumabAstraZenecaApproved
✅OsimertinibAstraZenecaApproved
✅GefitinibAstraZenecaApproved
✅Gefitinib + PlaceboAstraZenecaApproved
✅CrizotinibPfizerApproved
✅crizotinibPfizerApproved
✅NivolumabBristol Myers SquibbApproved

Hype Score Breakdown

Clinical
12
Activity
4
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05651269Phase 2UNKNOWN

Competing Products

20 competing products in NSCLC

See all competitors
ProductCompanyStageHype Score
Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/CarboplatinWuXi BiologicsPhase 3
37
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
BBP-398 + osimertinibLianBioPhase 1
11
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)BioAtlaPhase 1/2
26
YH42946YuhanPhase 1/2
39
HER3-DXd + HER3-DXd + Osimertinib + Osimertinib + HER3-DXd + HER3-DXd + OsimertinibDaiichi SankyoPhase 1
33
U3-1287 + Erlotinib + PlaceboDaiichi SankyoPhase 1/2
32
DS-1205c + OsimertinibDaiichi SankyoPhase 1
21
Datopotamab deruxtecan (Dato-DXd) + DocetaxelDaiichi SankyoPhase 3
47
Datopotamab deruxtecan + Durvalumab + Carboplatin + AZD2936 + MEDI5752 + AZD7789Daiichi SankyoPhase 1
33
Datopotamab deruxtecan + KEYTRUDA® + Carboplatin + CisplatinDaiichi SankyoPhase 1
33
HER3-DXd (FL-DP) + HER3-DXd (CTM-1 Lyo-DP) + HER3-DXd (CTM-3 Lyo-DP)Daiichi SankyoPhase 1
33
CS-7017 + erlotinibDaiichi SankyoPhase 2
35
gilteritinibAstellas PharmaPhase 1
36
OSI-906 + erlotinib + placeboAstellas PharmaPhase 2
35
naquotinib + midazolamAstellas PharmaPhase 1
29
OSI-906 + Erlotinib + PlaceboAstellas PharmaPhase 2
35
ExisulindAstellas PharmaPhase 1/2
32
naquotinibAstellas PharmaPhase 1
21
ASP8273Astellas PharmaPhase 2
27